Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions

BACKGROUND: IgPro20 is the first approved subcutaneous immunoglobulin (SCIg) preparation for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Two different doses of the SCIg preparation were investigated in the pivotal PATH study. Real-world data, and particul...

Descripción completa

Detalles Bibliográficos
Autores principales: Gingele, Stefan, Koch, Moritz, Saparilla, Anna Christina, Körner, Gudrun M., von Hörsten, Jarle, Gingele, Marina, Seeliger, Tabea, Konen, Franz Felix, Hümmert, Martin W., Neyazi, Alexandra, Stangel, Martin, Skripuletz, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053839/
https://www.ncbi.nlm.nih.gov/pubmed/33948119
http://dx.doi.org/10.1177/17562864211009100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053839/
https://www.ncbi.nlm.nih.gov/pubmed/33948119
http://dx.doi.org/10.1177/17562864211009100

Ejemplares similares